This study focuses on testing a medication called rocatinlimab (also known as AMG 451) for treating atopic dermatitis, a chronic skin condition that causes itchy, inflamed, and red skin. The study aims to determine how well this medication works and how safe it is for adolescents with moderate to severe forms of the condition.
The research will compare rocatinlimab against placebo in adolescents who have not responded well enough to previous treatments with topical corticosteroids. The study will last for 52 weeks, with the main evaluation of the medication’s effectiveness happening at week 24. During the study, researchers will monitor changes in the severity of skin symptoms and the intensity of itching.
Throughout the study, participants will receive either rocatinlimab or placebo through injections. The study will measure several aspects of the skin condition, including how much of the body is affected by the disease, the severity of symptoms, and improvements in itching and skin pain. This is known as a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving the actual medication versus the placebo during the treatment period.
Belgium 
Croatia 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Romania 
Spain 
